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Since the first recognized case of human infection with 
avian influenza H5N1 virus in 1997, the worldwide spread 
and re-emergence of this highly pathogenic influenza virus 
have led to 694 human infection cases. Of these cases, 402  
died from 2003 to 2015 (http://www.who.int/influenza/ 
human_animal_interface/EN_GIP_20150106Cumulative-  
NumberH5N1cases.pdf?ua=1), with a morbidity rate of 
57.9%, which is much higher than that of seasonal influenza 
H1N1 virus. The outbreak of the H7N9 virus epidemic in 
2013 has been a warning sign that the occurrence of new 
influenza pandemics and the sustained circulation of these 
viruses in poultry and other animals pose a persistent threat 
to public health. In addition, recent studies on influenza 
virus transmission proved that only a few amino acid muta-
tions are required to make H5N1 virus transmissible among 
ferrets, an animal model that resembles human response to 
influenza virus infection [1,2]. Considering the potential of 
mutated avian influenza virus being both easily transmitted 
and highly pathogenic to human, it is time to take measures 
before the next coming influenza pandemic. 
After entering its host cells, influenza virus first mas-
sively replicates, and then it induces acute and severe im-
mune responses, which lead to serious respiratory injuries 
and consequently acute lung injury (ALI) or acute respira-
tory distress syndrome (ARDS) [3]. At present, due to lim-
ited therapeutic strategies for influenza virus infection or 
ARDS, the mortality rate for humans infected with high 
pathogenic H5N1 remains high. Therefore, to find effective 
prophylactic or therapeutic agents that potentially alleviate 
H5N1 virus-induced lung injury should be of great im-
portance. 
Re-investigating existing drugs is an economical and 
time-saving approach to satisfy unmet medical needs be-
cause the safety, pharmacology, formulation and potential 
toxicity of shelved drugs have been largely established. Our 
previous study has shown that angiotensin II receptor 
blocker (ARB) losartan could effectively reduce ALI in-
duced by SARS-CoV [4]. We recently reported that avian 
influenza A H5N1 virus infection disrupted host ren-
in-angiotensin system (RAS) in mice and human plasma 
level of angiotensin II was markedly elevated in both H5N1 
and H7N9 infected patients [5,6]. Consisting with that, we 
found administration of recombinant human ACE2 protein 
effectively ameliorated the murine ALI induced by H5N1 
virus infection. Dysregulated angiotensin II level is highly 
associated with diseases such as hypertension and cardiac 
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Figure 1  Losartan can effectively ameliorate ALI induced by avian influenza A H5N1 virus infection in mice. A, Survival rate of C57/B6 mice receiving 
losartan or vehicle control once per day for continuously 4 days after intratracheal instillation of H5N1 virus. Survival rate data were collected from 27 mice 
per group. B, Wet/dry weight ratio, indicating the severity of lung edema, in H5N1-infected mice with or without losartan treatment. Lung tissues were ob-
tained on Day 7 after virus instillation. Data were from 6-7 mice per group. C, Representative lung histopathology of C57/B6 mice on Day 4 after virus 
infection following therapeutic treatment with losartan (lower panels) compared to non-treated group (upper panels). The original magnification was 200× 
(left panels) followed by an increased magnification (400×, right panels). Totally 100 fields were analyzed with 6 mice in each group. The bar graph stands 
for lung injury scores (left) and the number of infiltrating cells in infected lung tissues (right). Data were presented as mean±SEM. D, RT-qPCR analysis of 
M1 and M2 components of H5N1 virus. Data were presented as relative expression level of M1 and M2 to -actin 3–4 mice per group. E, RT-qPCR analysis 
of IL-6 expression relative to -actin in mouse lung tissues following therapeutic treatment with losartan or vehicle control. Data from 34 mice per group 
were analyzed. F, Western blot analysis of ACE and ACE2 expression in mouse lung tissues following losartan treatment, with -actin as internal control. 
Representative blots were shown (left), and a pool of four mice’s lung lysates was analyzed, presented as bar graphs and shown in the middle (for ACE) and 
on the right (for ACE2). Data were presented as mean of ACE- or ACE2-to--actin ratio±SEM from 4 mice in each group. *, P0.05; **, P0.01. 
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disease [7] and two classes of drugs have already been de-
veloped and clinically applied to maintain the normal func-
tion of RAS. The first class is ACE inhibitors (ACEis), 
which inhibit ACE from cleaving angiotensin I to generate 
angiotensin II. The second class is angiotensin II receptor 
blockers (ARBs), which block the interaction between an-
giotensin II and its type I receptor (AT1R) to suppress the 
downstream immune responses [8]. We thus hypothesized 
that these drugs, which demonstrated the same therapeutic 
consequence as increased ACE2 protein expression, may 
also be effective for the treatment of H5N1 infections. 
Previous studies have shown that ARBs perform better 
than ACEi in respiratory disorders such as ARDS induced 
by bacterial infection, as angiotensin II can be synthesized 
by some alternative enzymes such as chymase, cathepsin 
and trypsin [9,10]. Thus in our study, we focused on losar-
tan, the first orally active non-peptide selective ARB, to 
further investigate its therapeutic role in ALI induced by 
H5N1 virus.  
To test the potential therapeutic effect of losartan on ALI 
induced by live H5N1 virus, we used Losartan developed by 
DuPont Merck Pharmaceutical Co. under the code DuP753 
or MK954, which is a potassium salt of 2-n-butyl-4-chloro- 
5-hydroxymethyl-1-{(2′-[1H-tetrazol-5-yl]biphenyl-4-yl)me
thyl}imidazole [11], with a molecular mass of 461 Da. We 
found that administration of losartan at a dose clinically 
equivalent to human significantly improved the survival rate 
in H5N1 virus-infected mice (Figure 1A). Then, the severity 
of lung injury was determined by lung histopathology and 
the wet/dry lung weight ratio, which is an indicator of lung 
edema. Mice treated with losartan showed alleviated lung 
edema and improved lung histopathology, demonstrated as 
lowered lung injury scores and a reduced number of infil-
trating leukocytes (Figure 1B and C). Taken together, these 
results suggest that losartan, a conventional anti-hyperten- 
sion medication, is a promising strategy to ameliorate ALI 
and improve survival of mice infected with live avian in-
fluenza A H5N1 virus.  
Though effective when treated with Losartan, the viral 
load in the lung tissue of infected mice was not reduced 
after losartan treatment, indicating that losartan may not 
influence H5N1 viral entry or replication (Figure 1D). Since 
the binding of angiotensin II with AT1R promotes inflam-
mation and vascular permeability of lung tissue [12], which 
at least partially accounts for ALI induced by H5N1 virus, 
we supposed that the effect of losartan may result from a 
prevention of excessive downstream inflammatory respons-
es. In agreement with that, IL-6, one of the primary contrib-
utor cytokines downstream of AT1R, was also significantly 
down-regulated in losartan-treated group (Figure 1E). Fur-
thermore, a remarkable recovery of ACE2 expression and 
down-regulation of ACE in lung tissues of losartan-treated 
mice were also observed 48 h after H5N1 virus infection 
(Figure 1F). These data support the above notion that the 
mechanism of action of losartan in the context of H5N1 
influenza virus infection is mediated via RAS pathway.  
Dr. David Fedson has recently called for the use of statin, 
ARB, and ACEi in next influenza pandemic [13], and pre-
vious population-based study has clearly demonstrated that 
ARB inpatient application for severe pneumonia could sig-
nificantly reduce 30-day mortality rate in hospital [14]. 
Here, we further provided experimental evidence that losar-
tan and perhaps other ARBs should be considered as candi-
date therapies for clinical treatment of H5N1-infected pa-
tients. Herein randomized clinical trials on ARB treatment 
for ARDS are indeed in need. 
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